stars 1 stars 2 stars 3

Precision BioLogic develops, manufactures and markets innovative products for the clinical laboratory assessment of blood coagulation disorders. Our principal focus is in the field of hemostasis, for which we developed CRYOcheck, a line of specialized, high-quality frozen plasmas, reagents and integrated test kits used in the assessment of hemostasis. Precision currently serves over 1,000 clinical laboratories throughout North America with direct overnight delivery and works with distribution partners to sell to customers overseas. In November 2018, we acquired Affinity Biologicals, a primary manufacturer of thrombosis and hemostasis products, enabling us to expand our clinical and research offerings to include an extensive line of coagulation-related antibodies as well as other products and services. Most recently, in October 2025, we acquired George King Bio-Medical, a provider of hemostasis diagnostic products with close ties to the bleeding disorders community. All three organizations are committed to delivering high-quality products and services backed by knowledgeable, caring professionals.

Precision BioLogic Questions

The Precision BioLogic annual revenue was $8 million in 2026.

Paul Empey is the CEO of Precision BioLogic.

52 people are employed at Precision BioLogic.

Precision BioLogic is based in Dartmouth, Nova Scotia.

The NAICS codes for Precision BioLogic are [541, 62, 5417, 621, 54171, 6215, 541714, 54, 62151].

The SIC codes for Precision BioLogic are [80, 283, 28, 807].

Top Precision BioLogic Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users